Navigation Links
OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies
Date:3/20/2012

ROCKVILLE, Md., March 20, 2012 /PRNewswire/ -- OriGene Technologies today announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB™ brand. UltraMAB Antibodies are a collection of monoclonal antibodies which are exclusively developed by OriGene for IHC applications and are the industry's only antibody products available on the market that have been validated with the Company's breakthrough 10K High Density Protein Microarray Technology. OriGene's 10K High Density Protein Microarray Platform enables the screening of candidate antibodies against greater than 10,000 human proteins to identify the most specific monoclonal antibodies for IHC applications.

"High-specificity is the pre-requisite for any IHC antibody because IHC detection relies on only one antibody against a complex tissue sample. Through the use of novel and proprietary technologies such as our 10K High-Density Protein Microarray Platform, OriGene has dramatically improved the specificity of antibodies available to the global market place. By validating all UltraMAB antibodies against our 10K High-Density Protein Microarray Platform, the market now has access to one of the industry's most significant tools for IHC detection and determination of accurate results," said Dr. Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.

Each UltraMAB™ is validated for IHC and for immunoassay analysis, and determined to have no cross-reactivity with other human proteins other than the antibody's intended target protein as determined by OriGene's 10K High Density Protein Microarray Platform. Consequently, each UltraMAB™ is quality control verified, guaranteeing superior performance for IHC applications, where specificity-verification and the highest quality antibodies are critical for accurate detection.

Detailed information about the UltraMAB™ Antibodies is available at www.origene.com/UltraMAB, where customers can learn more about OriGene's unique approach to monoclonal antibody development and contact the company's representatives to explore collaborative opportunities.

OriGene will present the new line of UltraMAB™ Antibodies at the USCAP 2012 Annual Meeting in Vancouver, CA; March 17-23rd Booth # 827. To register for the company's free seminar presentation on UltraMAB™ please visit www.origene.com.

About OriGene Technologies

OriGene Technologies, Inc., is a biosciences company dedicated to develop gene centric innovative products and services to improve the quality of healthcare diagnostics and treatments. The Company's broadest collection of gene based products and services are important tools to accelerate the discovery of new diagnostics and drug treatments for better patient care. OriGene has one of the largest scale antibody production and highest quality process facilities in the world. For more information, visit www.OriGene.com.


'/>"/>
SOURCE OriGene Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Blue Belt Technologies to Showcase Navio™ PFS System at CAOS UK 2012 Conference in Glasgow, UK
4. Life Technologies Launches GeneArt® Precision TALs
5. BioStorage Technologies to Host Live Webinar on Optimizing the Value of Sample Assets
6. PLC Announces Ministry of Health Approval to Distribute RenalGuard® in Israel Through A.M.I. Technologies, Ltd.
7. Omnicell to Exhibit at Dubai International Pharmaceuticals and Technologies Conference and Exhibition
8. Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial
9. Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies
10. Medical Care Technologies Inc. Announces Adjournment of Special Meeting
11. BioStorage Technologies Integrates Sample Preparation Services into European Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Mass. , Feb. 9, 2016  Insulet Corporation (NASDAQ: ... tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s Board ... of nine directors, eight of whom are independent. ... 40 years of audit and finance experience and a deep ...
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... Bermuda, Feb. 9, 2016  Axovant Sciences Ltd. ... on the treatment of dementia, today announced further ... cognitive, behavioral and functional aspects of Lewy body ... in the U.S. Two out of the three ... expected to start later this quarter. In addition, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... The ... 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | Ticket ... Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation , ...
(Date:2/10/2016)... DC (PRWEB) , ... February 10, 2016 , ... Anxiety ... level since the start of Medicare Part D a decade ago, according to ... comments from older adults on how they are coping with rapidly rising costs. ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent article ... the number of patients under the age of 30. According to Southern California based ... offices, and may indicate an overall shift in the rapidly growing social acceptance of ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... Medicaid beneficiaries who are diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, ... treatment using applied behavior analysis (ABA) is key to providing effective treatment for ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
Breaking Medicine News(10 mins):